TCAng05: Novel Therapeutic to Treat Triple Negative Breast Cancer

TCAng05, a novel analog of the natural, non-toxic Angiotensin-(1-7) [Ang-(1-7)] hormone, has dual cancer-fighting and cardiovascular-protective properties, making it a safe, effective biologic alternative to chemotherapy for the treatment of triple-negative breast cancer.

Problem

Triple-negative breast cancer, the most aggressive breast cancer known, is negligibly low in expression of the estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, making it difficult to treat because of the need for combination therapy. Unlike for treatment of other breast cancer subtypes such as ER-positive and HER2-positive subtypes, there is no approved treatment for triple-negative breast cancer other than chemotherapy (e.g., nanoparticle paclitaxel, capecitabine, etc.), which is toxic to healthy cells.

Ang-(1-7), a heptapeptide hormone, is known to possess anti-proliferative, anti-angiogenic, anti-inflammatory and anti-fibrotic properties, which make it an ideal candidate for the treatment of triple-negative breast cancer. However, Ang-(1-7) is limited by poor stability and oral activity and thus has low potential as a commercial cancer product.

Solution

Researchers at Wake Forest Baptist Medical Center have developed TCAng-05, a novel analog of the naturally occurring hormone Ang-(1-7). Ang (1-7) has demonstrated positive proof of concept in cell lines and in animal models to be effective in treating triple negative breast cancer. Ang(1-7) also demonstrated an excellent safety profile in a Phase I human trial..

TcAng-05 was developed as a drug-able form of Ang(1-7) and has demonstrated superior characteristics including oral bioavailability, increased potency, and increased stability. Importantly, because it is a naturally occurring endogenous hormone with demonstrated safety, TCAng-05 is a safe, biologic alternative to first line therapy using traditional chemotherapy regimens, known to have significant toxicities.

Competitive Benefits

  • Targets proliferating cancer cells with minimal effects on non-cancer cells
  • Maintains normal blood pressure, heart rate or wound healing, unlike traditional chemotherapy treatments
  • Alternative, safer, non-chemotherapy treatment for triple negative breast cancer
  • Strong proprietary position
  • Stable compound with oral activity.

Application Fields

Non-Small Cell Lung cancer, breast cancer, prostate cancer, and sarcomas

Stage of Development

A successful phase I clinical trial of natural Ang-(1-7) for second or third line treatment of patients with metastatic or unresectable sarcomas is complete. TCAng05 has demonstrated effective inhibition of cancer cell growth in vitro and of tumor growth in a mouse model of triple negative breast cancer. A family of cyclic peptide analogs based on the TCAng05 structure has been exemplified, characterized in-vitro, and a reproducible, scalable synthesis of TCAng05 has been established.

Inventors

  • Ann Tallant, PhD, Department of Hypertension & Vascular Research Center
  • Patricia Gallagher, PhD, Department of Hypertension & Vascular Research Center
  • Carlos Ferrario, MD, Department of Surgical Sciences

Keywords

Angiotensin-(1-7), TCAng05, MAS receptor, agonist, breast cancer, prostate cancer, sarcoma, non-toxic chemotherapeutic

Patent Status

U.S, Patent No. 8,034,781, U.S. Patent No. 7,122,523, U.S. Patent No. 7,375,073, U.S. Application No. 62/220,711, PCT Application No. PCT/US2016/052216

Publications

Petty, W.J. et. al. (2009) Phase I and Pharmacokinetic Study of Angiotensin-(1-7), an Endogenous Antiangiogenic Hormone. Clin Cancer Res. 15 (23):7398-404.

Licensing Contact

Peter Golikov, MS, MBA, CLP
Licensing Director, Center for Technology Innovation & Commercialization
pgolikov@wakehealth.edu
+1.336.713.1664

Ref #: WFU 02-06, WFU 14-78

Back to Top